RDY Dr Reddy's Laboratories Ltd
- 69.300
- -0.350-0.50%
- 69.300
- 0.0000.00%
Dr Reddy's Laboratories Ltd News
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading
Asian equities traded in the US as American depositary receipts eased Thursday morning, declining 0.04% to 1,950.23 on the S&P Asia 50 ADR Index and paring earlier losses. From North Asia, the gainers
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
Asian equities traded in the US as American depositary receipts rose Wednesday morning, climbing 0.71% to 1,938.23 on the S&P Asia 50 ADR Index. From North Asia, the gainers were led by e-commerce fas
Asian Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading
Asian equities traded in the US as American depositary receipts were trending modestly higher Tuesday morning, rising 0.36% to 1,911.18 on the S&P Asia 50 ADR Index. From North Asia, the gainers were
Dr Reddy's Laboratories Ltd To Go Ex-Dividend On July 30th, 2024 With 0.47917 USD Dividend Per Share
May 11th - $Dr Reddy's Laboratories Ltd(RDY.US)$ is trading ex-dividend on July 30th, 2024. Shareholders of record on July 15th, 2024 will receive 0.47917 USD dividend per share. The ex-dividend d
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week 1% Lower
Asian equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.46% to 1,899.41 on the S&P Asia 50 ADR Index. Despite the gain, the index is down nearly 1
Asian Equities Traded in the US as American Depositary Receipts Trend Lower Thursday
Asian equities traded in the US as American depositary receipts were trending lower Thursday morning, declining 0.39% to 1,887.04 on the S&P Asia 50 ADR Index. From North Asia, the gainers were led by
Dr Reddy's Labs Price Target Raised to $81.00/Share From $80.00 by Barclays
Dr Reddy's Labs Price Target Raised to $81.00/Share From $80.00 by Barclays
Dr Reddy's Labs Is Maintained at Overweight by Barclays
Dr Reddy's Labs Is Maintained at Overweight by Barclays
Barclays: Maintaining the Dr. Reddy's Laboratories (RDY.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $80.00 to $81.00.
Barclays: Maintaining the Dr. Reddy's Laboratories (RDY.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $80.00 to $81.00.
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $81
Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $80 to $81.
Dr Reddy's Laboratories Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 13.56% Barclays $80 → $81 Maintains Overweight 01/29/2024 12.15% Barclays $75 → $80 Maintains O
Dr. Reddy's Laboratories Limited (NYSE:RDY) Q4 2024 Earnings Call Transcript
Asian Equities Traded in the US as American Depositary Receipts Trend Slightly Lower in Wednesday Trading
Asian equities traded in the US as American depositary receipts were trending slightly lower Wednesday morning, declining 0.17% to 1,893.63 on the S&P Asia 50 ADR Index. From North Asia, the gainers w
Earnings Call Summary | Dr Reddy's Laboratories Ltd(RDY.US) Q4 2024 Earnings Conference
The following is a summary of the Dr. Reddy's Laboratories Limited (RDY) Q4 2024 Earnings Call Transcript:Financial Performance:Dr. Reddy's reported full-year revenues of $3.3 billion, indicating an a
Dr Reddy's Laboratories Ltd | 6-K: Report of foreign private issuer (related to financial reporting)
Asian Equities Traded in the US as American Depositary Receipts Drop Sharply in Tuesday Trading
Asian equities traded in the US as American depositary receipts were trending sharply lower Tuesday morning, declining 1.36% to 1,897.97 on the S&P Asia 50 ADR Index.
Press Release: Dr. Reddy's Q4 & Full Year FY24 Financial Results
Dr. Reddy's Q4 & Full Year FY24 Financial Results HYDERABAD, India--(BUSINESS WIRE)--May 07, 2024-- Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today an
Dr. Reddy's Laboratories Fiscal Q4 Earnings, Revenue Gain
Dr. Reddy's Laboratories (RDY) reported fiscal Q4 earnings Tuesday of $0.94 per diluted share, up from $0.69 a year earlier. A sole analyst polled by Capital IQ expected $0.62. Revenue for the quarter
Dr Reddy's Laboratories Q4 2024 GAAP EPS ₹78.35 Beats ₹67.78 Estimate, Sales ₹70.830B Miss ₹70.911B Estimate
Dr Reddy's Laboratories Q4 2024 GAAP EPS ₹78.35 Beats ₹67.78 Estimate, Sales ₹70.830B Miss ₹70.911B Estimate
Dr. Reddy's Laboratories 4Q Rev INR70.83B Vs. INR62.97B >500124.BY
Dr. Reddy's Laboratories 4Q Rev INR70.83B Vs. INR62.97B >500124.BY
Analysis
Price Target
No Data
